Cutaneous candidiasis
Pro Research Analysisby 
Searched over 200M research papers for "cutaneous candidiasis"
Cutaneous Candidiasis: Causes, Risk Factors, and Pathogenesis
Cutaneous candidiasis is a common fungal infection of the skin caused primarily by Candida albicans, though other species like C. glabrata, C. krusei, C. tropicalis, and C. parapsilosis can also be involved Shahabudin2024Bilal2022Sanchez2021. The infection often affects areas where skin is moist and occluded, such as skin folds, and is characterized by red plaques with satellite lesions . While Candida species are normal commensals on human skin, certain conditions—such as immunosuppression, diabetes, and limited mobility—significantly increase susceptibility to infection Lu2023Kirkpatrick1988Shahabudin2024+1 MORE. Diabetes, in particular, is a major risk factor, leading to a higher prevalence of cutaneous candidiasis and related complications in affected individuals .
Diagnosis and Clinical Presentation of Cutaneous Candidiasis
Diagnosis is typically made through visual inspection, supported by laboratory tests such as potassium hydroxide (KOH) preparation, fungal cultures, or molecular identification techniques . Cutaneous candidiasis can present in various forms, including intertrigo, diaper dermatitis, cheilitis, and nail infections, and may occur in both immunocompetent and immunocompromised individuals Taudorf2019Kirkpatrick1988Shahabudin2024+1 MORE.
Immune Response and Chronic Mucocutaneous Candidiasis
The immune system plays a crucial role in controlling Candida infections. Defects in cell-mediated immunity, especially T-lymphocyte responses, predispose individuals to chronic or recurrent infections, as seen in chronic mucocutaneous candidiasis (CMC) Lu2023Kirkpatrick1988Kashem2016. In CMC, patients often experience persistent skin, nail, and mucous membrane infections, and relapses are common unless underlying immune defects are addressed Kirkpatrick1988Kashem2016.
Antifungal Treatment Strategies for Cutaneous Candidiasis
Topical Antifungal Therapies
Topical antifungal agents are the mainstay of treatment for cutaneous candidiasis. Clotrimazole, nystatin, and miconazole are the most studied and widely used topical drugs, showing high cure rates (73%–100%) and mild adverse effects Taudorf2019Bilal2022. Single-drug therapy is generally as effective as combination therapies that include antibacterial agents or corticosteroids .
Systemic Antifungal Therapies
Systemic therapy is reserved for more severe or widespread cases. Oral fluconazole has demonstrated efficacy comparable to topical clotrimazole and is the primary evidence-based systemic option Taudorf2019Sanchez2021. Other systemic agents, such as ketoconazole, have also been used, but fluconazole remains the preferred choice due to its safety and availability .
Antifungal Susceptibility and Resistance Patterns
Most Candida albicans isolates remain highly susceptible to nystatin, amphotericin B, and 5-flucytosine, with lower susceptibility rates observed for terbinafine and miconazole . Non-albicans species may show variable resistance, highlighting the importance of antifungal stewardship and susceptibility testing in guiding therapy .
Emerging and Advanced Treatment Approaches
Recent advances in drug delivery, such as farnesol-loaded ethosomes and dissolving microneedle patches containing itraconazole nanocrystals, have shown promise in enhancing drug penetration and efficacy against cutaneous candidiasis in experimental models Shen2024Permana2020. These novel approaches may offer improved outcomes, especially in cases involving biofilm formation or deep-seated infections Shen2024Permana2020.
Conclusion
Cutaneous candidiasis is a prevalent skin infection, especially among individuals with compromised immunity or diabetes. Diagnosis relies on clinical and laboratory findings, and most cases respond well to topical antifungal agents like clotrimazole, nystatin, and miconazole. Systemic therapy with fluconazole is effective for more severe cases. Ongoing research into advanced drug delivery systems and a better understanding of host immune responses may further improve management and outcomes for patients with cutaneous candidiasis Taudorf2019Lu2023Kirkpatrick1988+6 MORE.
Sources and full results
Most relevant research papers on this topic
Experimental cutaneous candidiasis in rodents.
This study developed an animal model of cutaneous candidiasis, allowing for greater manipulation and control in investigations of cutaneous candidiasis and factors influencing neutrophil accumulation in the epidermis.
Chronic mucocutaneous candidiasis
Chronic mucocutaneous candidiasis is a group of syndromes involving skin, nails, and mucosa infections with Candida albicans, and often involves abnormalities in cell-mediated immunity, predisposing patients to infections with opportunistic organisms like Candida spp.
Candida albicans skin infection in diabetic patients: An updated review of pathogenesis and management
Diabetes increases vulnerability to various types of cutaneous candidiasis, necessitating comprehensive understanding for effective management planning and prevention.
Antifungal susceptibility pattern of Candida isolated from cutaneous candidiasis patients in eastern Guangdong region: A retrospective study of the past 10 years
Candida albicans is highly susceptible to terbinafine, miconazole, and other azole drugs, while C. glabrata shows resistance to miconazole.
A rare case report: Cutaneous Candida tropicalis infection disguised as a sacral decubitus rash in an immunocompetent individual.
Early diagnosis of cutaneous lesions in patients with limited mobility is crucial, as Candida tropicalis can present in unusual locations and can cause severe fungal infections.
Dissolving Microneedle-Mediated Dermal Delivery of Itraconazole Nanocrystals for Improved Treatment of Cutaneous Candidiasis.
Incorporating itraconazole nanocrystals into dissolving microneedles improves cutaneous candidiasis treatment by enhancing antifungal activity and facilitating skin delivery into the infection site.
DOI